Posts by: Daniela Semedo, PhD

Daniela Semedo, PhD

Daniela holds a PhD in Clinical Psychology from The University of Edinburgh, United Kingdom, a MSc in Health Psychology and a BSc in Clinical Psychology. Her work has been focused on vulnerability to psychopathology and early identification and intervention in psychosis.

September 16, 2015November 5, 2015

Reata Announces Presentation of Initial Phase 2 Data on Bardoxolone Methyl for PAH at 2015 CHEST Meeting

News, Pulmonary Hypertension

Irving, Texas-based Reata Pharmaceuticals, Inc, recently announced that it will present initial data evaluating bardoxolone methyl in patients with pulmonary arterial hypertension (PAH) who are on stable background therapy during the 2015 ... Read more

September 15, 2015November 6, 2015

Cytori Therapeutics’ Scleroderma Therapy Shows Promising Results After 12 Months of Treatment

News, Scleroderma

Cytori Therapeutics a late stage cell therapy company developing autologous cell therapies from adipose tissue to treat a variety of medical conditions, recently announced the results from a 12-month follow-up of patients ... Read more

September 14, 2015September 14, 2015

DelMar Pharmaceuticals Presents Planned Clinical Trial Protocol for Non-Small Cell Lung Cancer Therapy

Lung Cancer, News

DelMar Pharmaceuticals, Inc. a biopharmaceutical company that develops and commercializes new treatments for cancer, recently presented an outline of its planned clinical trial protocol for its lead drug candidate VAL-083 (dianhydrogalactitol) for ... Read more

September 2, 2015September 2, 2015

Patients With COPD, Heart Disease Found To Benefit From Cardiopulmonary Rehabilitation

News

In a recent review published in the journal Breath, a team of researchers from the Faculty of Physical Education and Sports Sciences, National and Kapodistrian University of Athens in Athens, ... Read more

August 31, 2015November 5, 2015

Gilead Sciences Publishes Data From AMBITION Study of Treatment With Letairis and Tadalafil in Pulmonary Arterial Hypertension

News, Pulmonary Hypertension

Gilead Sciences, Inc., a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical needs, recently announced detailed data from its AMBITION randomized, double-blind, multicenter ... Read more

August 27, 2015November 5, 2015

Researchers Assess Best Exercise Protocol for Pulmonary Hypertension Patients

News, Pulmonary Hypertension

An award of $465,000 from the National Institutes of Health was recently granted to a physical therapy researcher from the IU School of Health and Rehabilitation Services at Indiana University-Purdue University ... Read more

August 27, 2015November 5, 2015

Actelion to Present Data on Selexipag (Uptravi) and Macitentan (Opsumit) for PAH at Upcoming European Conference

News, Pulmonary Hypertension

Actelion Ltd, a leading biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for diseases with significant unmet medical needs, recently announced that the results of its ... Read more

August 26, 2015November 6, 2015

Study Shows Systemic Inflammation in At-risk Mothers During Pregnancy May Indicate Early-onset Asthma

Asthma, News

Results from a study recently published in the Annals of Allergy, Asthma & Immunology showed that systemic inflammation in at-risk mothers during pregnancy may be indicative of a prenatal environment ... Read more

August 25, 2015November 6, 2015

Teva Announces EMA Validation of Reslizumab Marketing Authorization Application

Asthma, News

eva UK Limited, one of the UK’s top ten pharmaceutical manufacturers, recently announced the successful filing of a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMA) for its ... Read more

August 24, 2015November 6, 2015

Study Shows Tralokinumab Does Not Significantly Reduce Asthma Exacerbations in Patients With Severe Uncontrolled Asthma

Asthma, News

Results from a recent study published in The Lancet Respiratory Medicine showed that Tralokinumab did not significantly reduce the rates of asthma exacerbation in patients with severe uncontrolled asthma. However, ... Read more